高级检索
当前位置: 首页 > 详情页

Lobectomy Versus Sub-lobectomy for Clinical Stage IA (≤2 cm) Lung Squamous Cell Carcinoma with Tumour Spread through Air Spaces: A Multi-Centre Retrospective Study

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Department of Thoracic Surgical Oncology, Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200030, China. [2]Department of Cardiothoracic Surgery, The Affiliated Lihuili Hospital of Ningbo University, Ningbo 315040, China. [3]Department of Cardiothoracic Surgery, The First Affiliated Hospital of Ningbo University, Ningbo 315020, China. [4]Department of Thoracic Surgery, Putuo District People's Hospital, Zhoushan 316100, China. [5]Department of Integrated Traditional Chinese and Western Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai 200030, China. [6]Department of Thoracic Surgery, Shanghai Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200050, China. [7]Department of Emergency and Critical Care Medicine, The First People's Hospital of Fuyang Hangzhou, Hangzhou 311400, China. [8]School of Life Science and Technology, ShanghaiTech University, Shanghai 201210, China. [9]Department of Cardiothoracic Surgery, Ningbo Beilun District People's Hospital, Ningbo 315800, China. [10]Department of Internal Medicine, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China. [11]Department of Thoracic Surgery, The First Affiliated Hospital of Shaoyang University, Shaoyang 422001, China. [12]Department of Thoracic Surgery, The Central Hospital of Shaoyang, Shaoyang 422000, China. [13]Hospital's Office, Wenzhou People's Hospital, Shanghai University, Wenzhou 325000, China.
出处:
ISSN:

关键词: lung squamous cell carcinoma spread through air spaces lobectomy sub-lobectomy overall survival recurrencefree survival

摘要:
The efficacy of sub-lobectomy for clinical IA (tumours ≤2 cm) lung squamous cell carcinoma with tumour spread through air spaces (STAS) remains unknown. This study compares long-term survival outcomes between sub-lobectomy and lobectomy, aiming to offer pivotal evidence for optimizing resection strategies for clinical IA STAS-positive squamous cell carcinoma patients.Consecutive clinical IA STAS-positive squamous cell carcinoma patients undergoing surgery between 2010 and 2020 at 7 high-volume institutions across 5 Chinese cities were retrospectively reviewed. The primary end-point was overall survival, and the secondary end-point was recurrence-free survival. Propensity-score matching was employed to mitigate selection bias.A total of 870 patients were included, and propensity-score matching yielded 476 and 238 cases in the lobe and sub-lobe groups, respectively. Over an estimated median follow-up of 6.51 years, lobectomy significantly improved overall survival (hazard ratio [95% confidence interval] = 0.598 [0.447-0.761], P < .001) and recurrence-free survival (hazard ratio [95% confidence interval] = 0.572 [0.449-0.733], P < .001), and reduced postoperative mortality (30.7% vs 40.3%, P = .010) and recurrence (39.3% vs 55.0%, P < .001) incidences compared to sub-lobectomy. Further subgroup analysis revealed that lobectomy improved survival outcomes over sub-lobectomy in younger (age <70 years) and clinical IA2 sub-cohorts, while the 2 approaches yielded comparable survival outcomes for elderly (age ≥70 years) and clinical IA1 sub-cohorts.Lobectomy improved survival outcomes over sub-lobectomy for clinical IA STAS-positive squamous cell carcinoma and thus might be preferred for clinical IA squamous cell carcinoma patients with highly suspected STAS. The prognostic benefits of lobectomy may be discriminated by age and clinical stage.© The Author(s) 2025. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.

基金:
语种:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2025]版:
大类 | 2 区 医学
小类 | 2 区 外科 3 区 心脏和心血管系统 3 区 呼吸系统
最新[2025]版:
大类 | 2 区 医学
小类 | 2 区 外科 3 区 心脏和心血管系统 3 区 呼吸系统
JCR分区:
出版当年[2023]版:
Q1 SURGERY Q2 CARDIAC & CARDIOVASCULAR SYSTEMS Q2 RESPIRATORY SYSTEM
最新[2024]版:
Q1 SURGERY Q2 CARDIAC & CARDIOVASCULAR SYSTEMS Q2 RESPIRATORY SYSTEM

影响因子: 最新[2024版] 最新五年平均 出版当年[2023版] 出版当年五年平均 出版前一年[2022版] 出版后一年[2024版]

第一作者:
第一作者机构: [1]Department of Thoracic Surgical Oncology, Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200030, China.
共同第一作者:
通讯作者:
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:28509 今日访问量:5 总访问量:1589 更新日期:2025-09-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 首都医科大学附属北京同仁医院 技术支持:重庆聚合科技有限公司 地址:北京市东城区东交民巷1号(100730)